Laura Marks

If you DM me your email I can email you our nurse navigator handbook we developed for our program.

And yes to unhouse folks. Although we do ask where they plan to store their meds and help them think through different options or if they want our case manager to help dispense week at a time.

Unfortunately that and prison are the only two locations we can’t do it for.

We do it for skilled nursing facilities, jails, recovery housing, pts going home etc. but acute rehab rules prevent it.

ID docs bill for a normal inpt consult & The bonus for pts is no clinic appt needed - just a lab visit for SVR at some point (or in many cases we grab SVR labs the next time they are hospitalized or in the ED). Current SVR rate for the program is 74%.
Treatment failure rate is 2%, rest lost to care.

Most of the time we start the med at the time of discharge- but we set everything up while inpt (lab workup, Prior auth) &deliver meds to beds the day prior to discharge. No extra cost to inpt pharmacy!!
Patients leave hosp with a full course of HCV meds in hand & start tx home day of discharge.

The Opportuni-C trial showed how important this is. Our program demonstrates that these Inpatient starts and HCV meds on discharge are *doable* and *scalable* in our US healthcare system 🥳. Because the hospital is a healthcare access point!

@madelinemc5.bsky.social and I are excited to share that our HCV rapid start program at WashU ID has delivered over 200 courses of HCV meds to the bedside for inpatients at BJH! This allows people to start HCV rx at discharge, just like they would for any other new med prescribed on discharge.

Who's Going to Get Lenacapavir for HIV Prevention? At the International AIDS Conference this past summer, Dr. Linda-Gail Bekker brought down the house presenting the results of the PURPOSE 1 trial of twice-yearly injectable lenacapavir for prevention ...

With the publication of PURPOSE 2 for PrEP in @nejm.org, and the stellar results, I wonder what’s going to happen once it gets approved for this indication. Should be interesting, to say the least! blogs.jwatch.org/hiv-id-obser...

Thankyou!!

Would love to be added. Thanks!

Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial Simplified approaches to HCV treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.

Re-infection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial

✅ Just Accepted
#IDsky

Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post program implementation: observational case-control study A four-component meningococcal B (4CMenB) vaccine program was introduced in adolescents in 2019 in South Australia. We aimed to evaluate long-term vaccine effectiveness (VE) and impact (VI) on gonococcal infection four years after implementation of the program.

Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post program implementation: observational case-control study

✅ Just Accepted
#IDSKy

A superb collection of free, practical guides and hands-on resources for authors looking to improve their scientific publishing skillset by @plos.bsky.social

plos.org/resources/wr...

This is such important data! So glad to see it out in print! Being able to offer our pregnant patients biktarvy has been such a game-changer 🥰

Such a treat to open my OFID inbox this morning and see so many amazing papers by teams from across the globe on care of PWUD with infections.

Hoping potential reviewers also feel the same way 😆🤩😆. Reviewer invites for all our #IDCircus friends forthcoming.